Advantage Alpha Capital Partners LP Nuvalent, Inc. Transaction History
Advantage Alpha Capital Partners LP
- $419 Million
- Q3 2024
A detailed history of Advantage Alpha Capital Partners LP transactions in Nuvalent, Inc. stock. As of the latest transaction made, Advantage Alpha Capital Partners LP holds 4,851 shares of NUVL stock, worth $460,505. This represents 0.12% of its overall portfolio holdings.
Number of Shares
4,851Holding current value
$460,505% of portfolio
0.12%Shares
1 transactions
Others Institutions Holding NUVL
# of Institutions
210Shares Held
59.5MCall Options Held
450KPut Options Held
619K-
Deerfield Management Company, L.P. (Series C) New York, NY20MShares$1.9 Billion38.02% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY5MShares$475 Million18.43% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.13MShares$392 Million0.01% of portfolio
-
Black Rock Inc. New York, NY3.02MShares$287 Million0.01% of portfolio
-
Perceptive Advisors LLC New York, NY2.98MShares$283 Million7.96% of portfolio
About Nuvalent, Inc.
- Ticker NUVL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 42,977,800
- Market Cap $4.08B
- Description
- Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferr...